High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
about
Hepatic steatosis: a benign disease or a silent killerHepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environmentHepatitis C virus infection and type 1 and type 2 diabetes mellitusNon-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic HepatitisTreatment responses in Asians and Caucasians with chronic hepatitis C infectionManaging chronic hepatitis C in the difficult-to-treat patientWeight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatmentImpact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations.Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C.Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.Treatment of hepatitis C virus infectionEffect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome.Evolution of interferon-based therapy for chronic hepatitis C.Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.Predicting the probable outcome of treatment in HCV patients.A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infectionThe hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistanceAssociation of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for InterventionPredicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantationChaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.Management of chronic hepatitis C virus infection: a new era of disease control.Hepatitis C: How should we manage the patient?Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese miceTreatment of hepatitis C: critical appraisal of the evidence.Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort studyIs liver disease a threat to patients with metabolic disorders?Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications.Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.Improving anti-hepatitis C virus therapy.Histological assessment of non-alcoholic fatty liver disease.
P2860
Q22305506-56663E67-3BC5-4A68-BEA7-1C99B479D08FQ26775018-1F67CB2E-4A0E-4174-BE86-D4B4F79E7735Q26829202-F1C3B642-2724-45E3-BBFC-551356051030Q27478313-2EC39F92-449A-47C2-ADFE-561FE8D4EE06Q27478329-5F615C17-C55C-4235-BC69-0B566B301104Q27480999-7F3771EE-5324-4DC9-9744-85275338BDFEQ27489011-998F6C49-9BD3-4FDA-8D3D-0778D1D4A262Q27490409-FCF2B143-E7B5-4CFA-98B4-C26D4F7D7211Q27490841-65A62E06-CF8A-44EE-8135-2FF83FA3AF74Q28729225-D6CA52A2-5321-4D56-B73E-C16AAFCC23A7Q30733177-9D7E9C0E-1D43-4798-A776-9E054C478621Q30892564-8A061CF4-A754-466E-B784-792F0ABFB3B4Q33788303-007227FA-0647-4098-97C3-4A533D7AC223Q33797446-C1BCE3B0-5FB9-4F2E-B3EC-A001A12333B0Q34023077-20571D69-EB86-45CB-B0C5-2B83A02E7A34Q34099424-75DC49DF-F1A1-4E80-830B-6B786F5C5A32Q34225234-E7C308EB-8089-4267-96BB-647A26F6C5A6Q34342092-B0E55680-192C-4AD2-8956-8F7BA0392E0DQ34365442-4310ED7C-844F-4F1E-9202-AEB0FA44DBC9Q34409039-31893F98-3FB0-4305-A8D7-49B757979974Q34432191-89E2D394-0132-4BBB-A788-C3C79511795CQ34469210-EBA6316F-D68C-4B74-8A7C-D320FCC5A013Q34621423-4FE5B094-7645-4130-90E2-A22BD932891DQ34996746-D12CA119-841F-434F-BD15-A43EBBF79ECFQ35105334-AC9E2815-9E22-47EF-894E-035D2DE4EFA8Q35237179-94880FB7-DBF9-49AB-A61B-2BC916A8C760Q35237341-DB35AEEA-124D-48C4-B91B-5DCCF439FBE9Q35621603-B9C6908A-4FAC-4CC2-8C2C-92ECF968B05EQ35626712-1094A2D6-C312-476A-877D-9DE6308CC23CQ35740155-5492435F-6021-4B35-92E5-148A181E584BQ35823410-4DD45375-5122-4AD5-8DBC-2CE8B6005716Q35882856-BA9B221D-5749-43C4-B0EB-8DD7D9C028CCQ36003873-6ED9CF5E-182A-4CAD-913E-DD16E701D419Q36082056-40B8EFA4-5C1A-4199-B3B1-EDA7C3C0E820Q36238748-E5BB0AC7-20C2-44A6-86E9-9616C702F223Q36265230-F7DFB796-9957-4EF3-9894-B02CC48265A5Q36286318-328C212A-EA03-439E-8BEA-C72BBCE4F4F5Q36327795-A84E3A0F-7447-4D78-9AC9-8F7A7171CBCCQ36569749-91250058-D586-4162-9AAD-43030F298379Q36634377-5EABD982-9A1D-4B51-A846-7B2391E9B695
P2860
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
High body mass index is an ind ...... atment in chronic hepatitis C.
@ast
High body mass index is an ind ...... atment in chronic hepatitis C.
@en
type
label
High body mass index is an ind ...... atment in chronic hepatitis C.
@ast
High body mass index is an ind ...... atment in chronic hepatitis C.
@en
prefLabel
High body mass index is an ind ...... atment in chronic hepatitis C.
@ast
High body mass index is an ind ...... atment in chronic hepatitis C.
@en
P2093
P356
P1433
P1476
High body mass index is an ind ...... atment in chronic hepatitis C.
@en
P2093
Brian L Bressler
Jenny Heathcote
Maha Guindi
P304
P356
10.1053/JHEP.2003.50350
P407
P577
2003-09-01T00:00:00Z